QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPSChina Warehouse
What is B7-33?
B7-33 is a single-chain peptide analogue of the relaxin-2 B-chain, engineered to selectively activate RXFP1 (relaxin family peptide receptor 1) while avoiding the native two-chain structure of relaxin-2. Studied for anti-fibrotic effects, collagen remodelling, vasodilation, and cardioprotection — without the insulin-like A-chain that complicates full relaxin manufacture. Represents a simplified, single-chain RXFP1 agonist for fibrosis and cardiovascular research. Research use only.
Research Applications
Anti-Fibrotic Research
Collagen I/III expression suppression, MMP upregulation, TGF-β pathway modulation
RXFP1 Receptor Pharmacology
Receptor binding kinetics, cAMP/PKA signalling, β-arrestin recruitment
Cardiac Fibrosis Models
Post-infarct remodelling, myocardial stiffness, cardiac fibroblast activity
Vasodilation & Vascular Biology
NO-mediated vasodilation, endothelial function, arterial compliance
Single-Chain Relaxin Analogue Studies
B7-33 vs full relaxin-2 pharmacodynamic comparison, potency, selectivity
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2413928-17-1 |
| Molecular Formula | Single-chain relaxin B-chain analogue, ~3,800 Da |
| Identity | MS molecular weight confirmed — every batch |
| Peptide Type | Relaxin B-Chain Peptide / RXFP1 Agonist |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (4 weeks) |
| Shelf Life | 24 months (unopened) |

